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abstract: This study was designed to provide a genome-wide analysis of the effects of luteinizing hormone (LH) versus steroid ablation/
replacementongeneexpressioninthedevelopedcorpusluteum(CL)inprimatesduringthemenstrualcycle.OnDays9–11ofthelutealphase,
female rhesus monkeys were left untreated (control) or received a GnRH antagonist Antide (A), A þ LH, A þ LH þ the 3b-hydroxysteroid
dehydrogenase inhibitor Trilostane (TRL) or A þ LH þ TRL þ a progestin R5020. On Day 12 of the luteal phase, CL were removed and
samples of RNA from individual CL were hybridized to AffymetrixTM rhesus macaque total genome microarrays. The greatest number of
alteredtranscriptswasassociatedwiththeablation/replacementofLH,whilesteroidablation/progestinreplacementaffectedfewertranscripts.
Replacement of LH during Antide treatment restored the expression of most transcripts to control levels. Validation of a subset of transcripts
revealed that the expression patterns were similar between microarrayand real-time PCR. Analyses of protein levels weresubsequently deter-
mined for twotranscripts. Thisisthe ﬁrst genome-wideanalysis ofLH and steroidregulationofgene transcription inthe developed primate CL.
Further analysis of novel transcripts identiﬁed in this data set can clarify the relative role for LH and steroids in CL maintenance and luteolysis.
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Introduction
Corpora lutea (CL) appear very similar, in terms of structure, function
and regulation, between old-world monkeys (rhesus macaques) and
humans. Humans and macaques have similar length menstrual cycles
(luteal phases of the cycles are approximately the same length),
neither relies on a uterine signal to induce luteolysis in non-gravid
cycles and both exhibit an absolute requirement for luteinizing
hormone (LH) from the anterior pituitary to maintain luteal struc-
ture–function (Stouffer, 2006).
Treatment of rhesus macaques with an antagonist of
gonadotrophin-releasing hormone (GnRH; Antide, to inhibit LH pro-
duction) results in rapid destruction of developed CL [as evidenced
by a dramatic drop in progesterone (P) secretion], but the functional
lifespan of these CL can be rescued by pulsatile administration of
exogenous LH (Duffy et al., 1999b). Primate CL are remarkably sen-
sitive to local LH levels as macaque luteinized granulosa/luteal cells
respond to acute LH stimulation by rapidly secreting P in vitro, and
LH pulses are entrained to P pulses by mid-luteal phase in vivo (Molsk-
ness et al., 1991; Stouffer, 2003). It is generally accepted that LH
exerts its effects on targets, i.e. luteal cells, via the LH receptor
(LHR), a seven transmembrane domain G-protein-coupled receptor
capable of activating adenylate cyclase in the ovary (Benyo and Zelez-
nik, 1997; Zeleznik and Somers, 1999; Priyanka and Medhamurthy,
2007), and in other cells/tissues (Ascoli et al., 2002). However, the
exact mechanism(s) by which LH exerts its luteotropic effects on
the primate CL have yet to be elucidated.
Local autocrine/paracrine factors produced in response to LH may
also be important in controlling CL structure–function. For example, it
is hypothesized that locally produced P is the primary luteotropin in
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i.e. the so-called ‘Rothchild hypothesis’ (Rothchild, 1981). Treatment
of rhesus monkeys during the mid-luteal phase with Trilostane (TRL),
an inhibitor of 3b-hydroxysteroid dehydrogenase (3b-HSD), results in
onset of premature luteolysis within 4 days of treatment (Duffy et al.,
1994). Luteal phase length is reduced by approximately half, whereas
endogenous LH levels remain relatively unchanged following TRL
administration. The so-called ‘genomic’ progesterone receptors
(PGRs; ligand-activated transcription factors) are present in macaque
luteal cells and co-localize with 3b-HSD, supporting the premise of
the Rothchild hypothesis (Stouffer and Duffy, 1995). But, receptors
for other sex steroids [e.g. estrogen receptor b (ESR2) and androgen
receptor (AR)] as well as mRNAs for putative membrane-associated
steroid receptors were also detected in primate CL (Duffy et al.,
1999a, 2000; Engmann et al., 2006). Genomic steroid hormone recep-
tors are ligand-activated transcription factors that bind to regulatory
elements on DNA with the assistance of several co-factors to
modify gene transcription (Lonard and O’Malley, 2005). Thus, the
actions of LH on CL structure–function are likely a composite of
direct LH receptor-mediated effects and indirect effects resulting
from LH-regulated local factors, e.g. steroids including P.
To investigate both the direct and indirect (via local steroids includ-
ing P) effects of LH on the primate CL during the menstrual cycle, an in
vivo model was developed in which ablation and replacement of LH
(Duffy et al., 1999b) and steroid ablation/progestin replacement
could be performed in rhesus monkeys during the same experimental
protocol (Young and Stouffer, 2004). Previous ablation/replacement
experiments on the primate CL focused primarily on the effects of
LH versus P on individual gene families, including proteases and cas-
pases involved in tissue reorganization (Young et al., 2002, 2004;
Young and Stouffer 2004; Peluffo et al., 2005).
Recently, attempts were made to broadly evaluate LH regulation of
genes in the macaque CL (Yadav et al., 2004; Xu et al., 2005). Xu
et al. (2005) either left rhesus monkeys untreated or administered a
single bolus of Antide in the mid-luteal phase, the CL were removed
and total cDNA hybridized to a limited (11 600 transcripts) human
spotted array. The resulting data successfully identiﬁed a novel group
of genes, including the corticotropin-releasing hormone (CRH)/urocor-
tin (UCN)-receptor-binding protein system, that appear to be involved
in the maintenance of CL structure/function (Xu et al., 2007). Yadav
et al. (2004) used the GnRH antagonist Cetrorelix&, administered to
bonnet monkeys in the mid-luteal phase, to identify changes in
mRNA transcripts by differential display. Seven transcripts, including
mRNA for low-density lipoprotein (LDL) receptor, were identiﬁed as
changing in expression after LH withdrawal (Yadav et al., 2004).
While these approaches were successful in identifying novel gene
regulation by LH in the CL, further opportunities now exist for global
(genome-wide) evaluation of gene activities in macaque tissues
(Noriega et al., 2007; Parent et al., 2008) including the rhesus CL
(Bogan et al., 2008b) using the AffymetrixTM Rhesus Macaque
Genome Expression Array. Building on these validated studies, we uti-
lized the rhesus array to further identify changes in gene expression in
the macaque CL in response to LH and steroid ablation/replacement
as described earlier. It was expected that LH-dependent changes in
gene expression (directly regulated by LH) could be contrasted and
compared with changes in the expression of genes that were steroid
(especially P) dependent (indirectly regulated by LH).
Materials and Methods
The studies were performed at the Oregon National Primate Research
Center (ONPRC) on the West Campus of Oregon Health & Science Uni-
versity (OHSU). All procedures and protocols were approved by the
ONPRC/OHSU Animal Care and Use Committee, in accordance with
the National Institute of Health (NIH) Guidelines for Care and Use of Lab-
oratory Animals. Adult, female rhesus macaques (Macaca mulatta) exhibit-
ing regular menstrual cycles were selected for the study and were under
the direct care of the ONPRC Division of Animal Resources (DAR).
Monkeys (n ¼ 22) received one of the following treatments for 3 days
beginning on Day 9 of the luteal phase (mid-luteal phase, the time of
peak CL function). Some females were left untreated to establish gene/
protein expression in normal CL (control group; n ¼ 4). Alternatively,
ablation of LH was accomplished by treating females with a GnRH antag-
onist [Antide obtained from the Contraceptive Development Branch,
Center for Population Research, National Institute of Child Health and
Human Development (NICHD), 3 mg/kg once per day, n ¼ 5]. This treat-
ment signiﬁcantly lowers LH and P levels within 1 day, with baseline levels
present by the end of the experimental period (Duffy et al., 1999b).
Recombinant human LH (40 IU, three times daily) was also administered
in a pulsatile manner (A þ LH; n ¼ 4), which returns systemic LH and P
to control levels (Duffy et al., 1999b). In addition, steroid production by
the CL in response to LH replacement was blocked by oral administration
of the 3b-HSD inhibitor TRL (A þ LH þ TRL; 600 mg b.i.d, n ¼ 4), which
suppresses systemic P levels and induces premature luteolysis at this
dosage and duration of treatment in rhesus monkeys (Duffy et al. 1994).
Actions of P were restored in a subset of TRL-treated animals by treat-
ment with a synthetic progestin, R5020 (A þ LH þ TRL þ R5020;
2.5 ng/ml once per day, n ¼ 5), at a dosage and duration that prevents
the indices of luteolysis brought on by TRL treatment in macaque
monkeys (Young and Stouffer, 2004). Following the 3-day treatment inter-
val, CL were surgically removed and half of each tissue was individually
processed for total RNA, and the other half for total protein as described
previously (Peluffo et al., 2005). Anesthesia of animals and lutectomy were
performed by the surgical veterinary staff (DAR, ONPRC) as described
previously (Duffy et al., 2000).
Microarray analysis and real-time
PCR validation
All rhesus macaque genome arrays were processed by the OHSU Affyme-
trix Microarray Core (AMC), OHSU. The AMC performed the RNA
expression proﬁling, ampliﬁcation and hybridization of samples (http://
www.ohsu.edu/gmsr/amc/amc_technology.html#assay). Following data
normalization using the robust multichip average algorithm, the web-based
GeneSifter& software (http://www.genesifter.net/web/) was used to
identify transcripts from log2-transformed data that signiﬁcantly changed
expression between treatment groups by pairwise comparison analysis
(t-test, P , 0.05), and for the entire experimental group by multiple com-
parison analysis procedures (one-way ANOVA, P , 0.05; see http://
www.genesifter.net/web/webinars.php for further explanation of analyti-
cal methods by GeneSifter&). The AffymetrixTM Rhesus Genome Array
contains 52 024 rhesus probe sets for approximately 47 000 rhesus tran-
scripts, plus several control probe sets; array design is based on the Baylor
School of Medicine’s rhesus macaque whole-genome shotgun
assembly and GenBankw sequence-tagged sites (STSs), expressed
sequence tag and mRNA sequences (http://www.affymetrix.com/
support/technical/datasheets/rhesus_datasheet.pdf). There are mul-
tiple probes sets (transcripts) for individual gene products on this array
(Spindel et al., 2005). Therefore, microarray data will be referred to as
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Data ﬁles were submitted to the Gene Expression Omnibus (www.
ncbi.nlm.nih.gov/geo: series GSE12 281). To validate the microarray
results, selected genes were analyzed by real-time PCR to quantify
changes in mRNA levels that occur following LH and/or P ablation/repla-
cement. The real-time PCR probes were designed as described pre-
viously (Xu et al., 2006) and labeled with the 50 reporter dye FAM and
the 30 quencher dye MGBNFQ. Sequences for real-time probes and
primers are listed in Table I, along with gene identiﬁers. All real-time
studies were performed and analyzed as reported previously (Xu et al.,
2006). The data were subjected to one-way ANOVA by the use of Sig-
maStat& software (Version 2.0). When signiﬁcant (P , 0.05), differences
between treatment groups were analyzed by pairwise multiple compari-
son procedures (Tukey test or Student–Newman–Keuls method as
appropriate).
Western blot analysis
Immunoblot (western blot) analysis was performed to permit comparison
of the patterns of protein levels of two selected gene products versus their
mRNA levels in individual CL. Electrophoresis was performed using gradi-
ent gels (10–20% liner with 4% stacking gel; BioRad Laboratories, Her-
cules, CA, USA) with 20 mg of protein in denaturing SDS loading buffer
(3% SDS, 7 mM EDTA, 7 mM EGTA, 7% glycerol, 0.36 M Tris, 3.6 mM
DTT and 3.6% bromophenol blue) per individual sample.
After electrophoresis, proteins were transferred to Immun-BlotTM
PVDF membranes (0.2 mM; BioRad) overnight at 48C. Membranes were
blocked with a neutral protein (3% NFM) at 48C overnight and then incu-
bated with the following primary antibodies according to the manufac-
turer’s protocols: mouse anti-human secreted frizzled related protein-4
(SFRP4) whole sera antibody (ﬁnal dilution 1:1000; Abnova/Afﬁnity Bior-
eagents H00006424-A01) or rabbit anti-human steroidogenic acute regu-
latory (StAR) protein (ﬁnal concentration 1 mg/ml; Fisher/Afﬁnity
Bioreagents PA1-560). All horseradish peroxidase-labeled secondary anti-
bodies were from the same source (Zymed Laboratories, Invitrogen
Corp., Carlsbad, CA, USA), speciﬁc to the host animal of the primary anti-
body, and used at a ﬁnal dilution of 1:2000.
For the quantiﬁcation of protein levels from individual CL, a luminescent
signal was generated using western blotting luminol reagent (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) and detected with Kodak
X-OMAT ﬁlm (Eastman Kodak Co., Rochester, NY, USA). Densitometry
analysis was performed using a gel documentation system and Quantity
One software (Bio-Rad). To quantify protein levels, the blots were
stripped by a gentle method (successive PBS and TBST washes, Abcam
Inc., Cambridge, MA, USA) to remove all antibodies. This method was
conﬁrmed for each antibody by incubation of stripped blots with only
the secondary antibody and then developed for any luminescent signal
as described earlier. Blots were then blocked again overnight and
re-probed for b-actin levels (Tesone et al., 2005) by incubation with the
primary antibody rabbit anti-human b-actin (0.8 mg/ml; Abcam ab8227),
and secondary antibody as before. All data were subject to one-way
ANOVA (similar to real-time PCR data) and are presented as the intensity
of protein of interest: b-actin intensity. Because of high background to
signal ratio for SFRP4 blots containing þTRL and þR5020 samples, for
both b-actin and SFRP4 samples, background intensity was subtracted
from average intensity for all bands (regardless of treatment group)
before normalization for SFRP4 expression.
For presentation of western blot data, samples from individual CL
were pooled by treatment group, and then pooled samples underwent
electrophoresis and transfer as stated earlier for the detection of each
protein of interest (StAR, SFRP4 and b-actin). Following electrophoresis
and protein transfer to PVDF membranes, StAR and b-actin blots were
developed via the WesternDotTM 625 Western Blot Kit (Invitrogen,
Molecular Probes) with the aforementioned primary antibodies accord-
ing to the manufacturer’s protocol; SFRP4 was developed as described
earlier.
Results
Normalized data ﬁles for individual arrays have been uploaded to the
National Center for Biotechnology Information’s Gene Expression
Omnibus gene expression repository (http://www.ncbi.nlm.nih.gov/
geo/ Series GSE12281). Of the more than 47 000 transcripts rep-
resented on the rhesus genome arrays, the multiple comparison analy-
sis of GeneSifter& identiﬁed 2% of all transcripts on the array as
changing in expression  2-fold between various treatments
(one-way ANOVA, P , 0.05); these were then analyzed by the
cluster analysis algorithm of GeneSifter& (for further description of
cluster analysis, see http://www.genesifter.net/web/resources_clus-
ter.php, and http://www.statsoft.com/textbook/stcluan.html for a
description of the cluster analyses performed by the GeneSifter& soft-
ware). The results are presented as a heat map showing relative levels
of expression in Fig. 1A. The heat map is divided into two regions:
region 1 (above the line) shows transcripts whose levels increased
(red) above controls following treatment with Antide, and region 2
depicts transcripts whose levels decreased (green) with Antide treat-
ment. The majority of transcripts were in the latter region, i.e. levels
decreased in expression following Antide treatment. Most transcripts
in both regions were restored to near-control levels by LH replace-
ment (see Table II for examples of transcripts not restored by LH
replacement, which compares the transcripts that differ signiﬁcantly
between the control and the AntideþLH groups). Many, but not all,
of the Antide-sensitive transcripts appear to be affected similarly
(either decreased or increased) by steroid withdrawal (TRL), but
several of these changes were not as pronounced. Treatment with
R5020 reversed many of the effects of TRL, but not necessarily to
the level observed with LH replacement.
These changes in transcript expression are depicted in Fig. 1B as a
pairwise comparison of the number of transcripts differing between
treatment groups. The largest number of differentially expressed tran-
scripts was associated with LH ablation/replacement, while steroid
ablation/replacement affected fewer transcripts (Fig. 1B). Hierarchical
cluster analysis of all treatment groups by GeneSifter& indicated that
the Control and AþLH groups were similar in gene expression,
whereas the Antide group was most related to the A þ LH þ TRL
and A þ LH þ TRL þ R5020 groups. Because a relatively small
number of transcripts differed  2-fold between the control and
A þ LH groups (n ¼ 36, Fig. 1B), the A þ LH group can be con-
sidered a separate ‘control’ for the steroid ablation/replacement
groups for the purpose of further analysis. Pathways signiﬁcantly [as
determined by z-score (Doniger et al., 2003) and ontology abundance]
affected by treatments ( 2-fold) are depicted by known gene ontol-
ogies in Table III. Many of these signiﬁcant ontologies are associated
with the production of steroids and steroid precursors (e.g. sterol bio-
synthetic processes and cholesterol biosynthetic processes), and a
number are related to the immune system/response (immunoglobulin
production, regulation of B cell activation, and others).
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Table I Real-time PCR primer and probe sequences used to validate microarray expression
Gene
a NCBI Accession Number Forward Primer (50–30) Probe (50–30) 6FAM-Sequence-MGBNFQ Reverse Primer (50–30)
MHC1 U84789 CAGATAGATAAGGCGGGAGCTACT CAGTGACAGTTCCC GCCGTGAGAGACACATCAGAAC
SFRP4 NM_001032962 CTGCGAGCCCCTCATGAA CACAGCTGGCCCGAA GTCATAGACGGGCAGCTCATC
CCL3 BV209119 GGCCTGCTGTAGGCAGTCAT CAGACTGACCAATGTGTATC ACAGCCCTGACCAAAAGCAT
CAT NM_001752 TCCATTCGATCTCACCAAGGT CAA GGACTACCCTCTCAT CCGGTTTAAGACCAGTTTACCAA
StAR BV208869 GTGCGTGTGTACAAGGCAGAA CGGCAGCCCTCTG GGTGTTGCTGTGCAGTGAATG
ADAMTS-5 XM_001103439 TTCATGTTTCCCTCAGATAGTGATG ACACATGTCATAGAAACAA TGGTTTATTTGCTCTAAGCCCTCTA
MMP-9 XM_001104871 AGGCGCTCATGTACCCTATGTAC CCCCCCTTGCATAAG TGCCGGATGCCATTCAC
MMP-19 XM_001111542 TGGCCCCCAACTCCATT TGTCTTAGACAGCCCTTC ACCATTGACCTCCAGAAAAGAGAT
CASP2 NM_032982 GCACTGAGGGAGACCAAGCA TCACCACCCTTTCCGGGCTTCAG CACAGCTCAACGGTGGGAGTA
IL1RN U65590 TGGCACTTGGAGACGTGTATG CCTCGGCCTGTCTC CGAGTCTTTTTTCCTGCTCTGAA
AHRIP NM_003977 TCCAAAAACGTGTGATACAGGAA CTCCCGGACTTTC TAGTGGAACGTGGCCTTGGT
ARNT2 BV208380 CCAGTCCCAGGGAATGAATG CTCCCGGCAGCACT CACGTTCTCGCATAGCTTATGG
VEGF M27281 X15997 ACGAAGTGGTGAAGTTCATGGA TCAGCGCAGCTACT CTCATCAGGGTACTCCTGGAAGA
PRLR NM_000949 AGCTGAGTGGGAGACCCATTT AAACAGAGTTTAAGATTCTC GCGAACCTGGACAAGGTATTTC
CRHBP NM_001882 GACAGACCCCAACCTCTTTCC CCCTGGTCGTTCCAC TGGAGAAGCTGCAGTTTCGA
INHBA BV166389 AGAGCACCTGGCACGTCTTC CAGCATCCAGCGGTT ACGTCCAGGGAGCTTTTTCC
SC4MOL AB169840 TGGAGTGTAGCGGCACAATC CGGCTCACTGCAAC GGAGGCTGAGGCAGGAGAAT
LOC693394 XM_001081982 CACGTCATCGACTACATCTTGGA CCTGGACTCGCATCC TCTGGTGATGGAGGCTGACA
ESR2 AB006589 TCAGTTGAGGTCAGGAGTTTGAAA CAACATGGCGAAACC ACCACCATGCCTGGCTAATT
AR NM_001032911 GCAGGCAAGAGCACTGAAGATA TGCTGAGTATTCCCC CCTTTGGTGTAACCTCCCTTGA
PGR XM_001095317 CATGTCAGTGGGCAGATGCT TATTTTGCACCTGATCTAA ATTCTTTCATCCGCTGTTCATTC
PGRMC1 XM_001100639 CCAGGACCCCCGCATAC CATGGCCATCAACG TTTGGTCACGTCGAACACCTT














.Several genes (n ¼ 22), representing transcripts identiﬁed from the
microarray data set as expressed in the macaque CL, were chosen for
validation by real-time PCR. These included novel genes with respect
to luteal function, steroid hormone receptors, previously determined
LH- and/or steroid-regulated genes, plus ‘negative control’ transcripts
that did not change in expression between groups. Table IV lists all
validated genes and summarizes the results of microarray expression
analysis and one-way ANOVA values for real-time PCR data. The
table is divided into examples of gene transcripts whose levels were
(i) not altered by treatments (not regulated), (ii) LH-regulated inde-
pendent of steroid inﬂuence and (iii) LH-regulated in a P or (iv)
other steroid-dependent manner. Typically, the patterns of mRNA
levels determined by real-time PCR resembled those from microarray
analysis (Table IV).
An example of a novel gene identiﬁed by microarray as being
LH-regulated in the primate CL is interleukin 1 receptor antagonist
(IL1RN), depicted in Fig. 2. The IL1RN gene belongs to the ‘negative
regulation of immune system process’ ontology based on known
Kyoto Encyclopedia of Genes and Genomes—KEGG pathways
(similar to Table III, which displays the number of transcripts with
known gene ontology pathways); many of the transcripts in this
ontology, including IL1RN, were mainly affected by LH ablation/repla-
cement, and to a lesser extent, by steroid ablation/P replacement
(Fig. 2A). Results from real-time PCR analysis were comparable with
those provided by microarray analysis (Fig. 2B); IL1RN mRNA levels
increased following Antide treatment, but this effect was prevented
by LH replacement. Treatment with TRL with or without R5020 repla-
cement was without effect.
Regulated members of the ‘steroid biosynthetic process’ ontology,
based on known KEGG pathways (similar to the results from Table III),
and two validated genes from this category are presented in Fig. 3.
Most of these transcripts are regulated similarly by LH and steroid
ablation (Fig. 3A) in that transcript levels declined with Antide or
TRL treatment. While LH replacement typically prevented the
decline induced by Antide, progestin replacement with R5020 was
less effective in preventing TRL’s effects, except in some instances
(e.g. STARD4, CYP19A1). Results from real-time PCR assays of the
prolactin receptor (PRLR; Fig. 3B) and sterol-C4-methyl oxidase-like
(SC4MOL; Fig. 3C) mRNAs were comparable with the results
obtained by microarray. Levels of both mRNAs were decreased by
Antide treatment, and LH replacement maintained levels similar to
control. Likewise, TRL treatment resulted in mRNA levels similar to
Figure 1 (A) Cluster analysis by multiple comparison procedure of GeneSifter& of all transcripts whose levels signiﬁcantly (P , 0.05) changed in
expression  2-fold when compared with control CL. The heat map indicates the relative levels of the expression of each transcript, with red indicating
increased expression and green indicating decreased expression. The line separates the two regions of different transcript expression: 1: increasing
expression with Antide treatment; 2: decreasing expression with Antide treatment. C, control; A, Antide; L, A þ LH; T, A þ LH þ TRL; R, A þ LH þ
TRL þ R5020. (B) Summary of pairwise comparison analysis of the number of transcripts identiﬁed by GeneSifter& as signiﬁcantly changing
expression  2-fold (Student’s t-test, P , 0.05) between indicated treatment groups. Comparisons between complimentary ablation/replacement
groups are indicated on the top, whereas pairwise comparisons between control and A þ LH, or A þ LH and A þ LH þ TRL þ R5020 treatments
are depicted below. For example, 1415 transcripts differ signiﬁcantly between the control and Antide treatment groups, whereas only 36 differ sig-
niﬁcantly between the control and Antide þ LH treatment groups. The number of transcripts whose expression differs between control, Antide and
A þ LH groups (black brackets) are greater than those between A þ LH, A þ LH þ TRL and A þ LH þ TRL þ R5020 groups (dashed brackets).
LH/steroid ablation/replacement in primate CL 185Antide, but R5020 replacement either did not affect mRNA levels
(PRLR; Fig. 3B), or only partially maintained mRNA at control levels
(SC4MOL; Fig. 3C).
The expression of transcripts for genomic steroid hormone recep-
tors as measured by microarray was low, and the pattern did not
change throughout the experimental groups; examples include the
.............................................................................................................................................................................................
Table II Transcripts not restored to control levels by LH replacement of Antide-treated CL ( 2-fold differences P < 0.05)







Mamu-DRB mRNA for major histocompatibility complex class II, partial cds, clone:R00205DR09 AB112035 Down 4.7
Pre-B-cell colony enhancing factor 1 AA873350 Down 4.3
Nuclear receptor subfamily 4, group A, member 1 NM_002135 Down 4.3
Prostaglandin F receptor (FP) NM_000959 Down 4.3
gDNA.Hs2.89418.2.S1 FEA ¼ U133PSR GEN ¼ PTGFR DEF ¼ Orthologous to 1555097_a_at
prostaglandin F receptor (FP)
BC035694 Down 4.2
Pre-B-cell colony enhancing factor 1 BF575514 Down 3.9
Low density lipoprotein receptor (familial hypercholesterolemia) AI861942 Down 3.6
V-fos FBJ murine osteosarcoma viral oncogene homolog BC004490 Down 3.4
gi:47777222 DEF ¼ TUBA1 _1214 Rhesus macaque genomic DNA Macaca mulatta STS genomic clone
MMA1214, sequence tagged site. GEN ¼ TUBA1 PROD¼tubulin, alpha 1
Down 3.3
Low density lipoprotein receptor (familial hypercholesterolemia) NM_000527 Down 3.3
Hypothetical protein LOC129293 (LOC129293), mRNA AA005361 Down 3.2
gDNA.Hs.106635.0.S2 FEA ¼ U133PSR GEN ¼ PIPPIN DEF ¼ Orthologous to 209981_at RNA-binding
protein pippin
AL023553 Down 3.0
Transcribed locus AI248760 Down 2.9
Pre-B-cell colony enhancing factor 1 BC020691 Down 2.7
Pre-B-cell colony enhancing factor 1 NM_005746 Down 2.4
Pre-B-cell colony enhancing factor 1 BF575514 Down 2.4
Endothelial cell-speciﬁc molecule 1 NM_007036 Down 2.4
Similar to nicotinamide phosphoribosyltransferase (NAmPRTase) (Nampt) (Pre-B-cell colony-enhancing
factor 1 homolog) (PBEF)
CB229989 Down 2.4
DIS3 mitotic control homolog (S. cerevisiae)-like 2 AI935717 Down 2.4
gi:47776579 DEF ¼ EHD3_613 Rhesus macaque genomic DNA Macaca mulatta STS genomic clone
MMA613, sequence tagged site. GEN ¼ EHD3 PROD ¼ EH-domain containing 3
Down 2.3
zinc ﬁnger, DHHC-type containing 19 NM_144637 Down 2.2
complement component 4B (Childo blood group) NM_000592 Down 2.2
Transcribed locus AI873273 Down 2.2
Aminolevulinate, delta-, synthase 1 NM_000688 Down 2.2
Transcribed locus, strongly similar to NP_057696.2 mitochondrial solute carrier protein [Homo sapiens] H69701 Down 2.0
Dual speciﬁcity phosphatase 1 AA530892 Down 2.0
Amine oxidase, copper containing 2 (retina-speciﬁc) NM_009590 Down 2.0
Similar to HLA class I histocompatibility antigen, A-74 alpha chain precursor (MHC class I antigen A*74)
(Aw-74) (Aw-19)
AF157401 Up 8.4
Neuronal pentraxin I NM_002522 Up 4.1
Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 NM_000602 Up 3.5
gi:47776712 DEF ¼ HP_143 Rhesus macaque genomic DNA Macaca mulatta STS genomic clone MMA143,
sequence tagged site. GEN ¼ HP PROD ¼ haptoglobin
Up 3.0
gi:47777186 DEF ¼ THBS1_279 Rhesus macaque genomic DNA Macaca mulatta STS genomic clone
MMA279, sequence tagged site. GEN ¼ THBS1 PROD ¼ thrombospondin 1
Up 2.6
Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 AL574210 Up 2.5
ADP-ribosylation factor-like 4C AW450363 Up 2.1
ARTC1 mRNA, complete sequence BF508813 Up 2.0
Serine/threonine kinase 17a AW194730 Up 2.0
aEffect of Antide, transcript not restored to near control levels by LH replacement.
bControl: Antide þ LH.
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Table III Ontologies signiﬁcantly impacted by LH and steroid ablation/replacement
a
Ontology List Array z-score %
b
Immune system
immunoglobulin production 5 13 6.09 38
regulation of B cell activation 5 16 5.33 31
production of molecular mediator of immune response 5 22 4.27 23
cellular defense response 10 53 5.25 19
B cell activation 8 46 4.40 17
response to inorganic substance 5 29 3.45 17
leukocyte differentiation 9 71 3.50 13
immune system development 13 135 3.08 10
negative regulation of immune system process 6 27 4.61 22
Steroid/cholesterol processes/metabolism
sterol biosynthetic process 11 30 8.77 37
cholesterol biosynthetic process 8 23 7.23 35
steroid biosynthetic process 17 62 9.02 27
sterol metabolic process 16 68 7.86 24
cholesterol metabolic process 13 61 6.58 21
steroid metabolic process 26 142 8.30 18
lipid biosynthetic process 32 222 7.53 14
Cellular morpohology
regulation of cell shape 5 31 3.26 16
regulation of cell morphogenesis 5 32 3.17 16
cell-substrate adhesion 10 70 4.14 14
myeloid cell differentiation 8 58 3.58 14
cell-matrix adhesion 9 66 3.76 14
chemotaxis 11 100 3.33 11
taxis 11 100 3.33 11
Cellular metabolism/biosynthesis
isoprenoid metabolic process 5 25 3.88 20
oxygen and reactive oxygen species metabolic process 6 31 4.15 19
water-soluble vitamin metabolic process 7 37 4.40 19
oxidoreduction coenzyme metabolic process 5 31 3.26 16
vitamin metabolic process 8 55 3.76 15
cofactor metabolic process 15 122 4.39 12
membrane lipid biosynthetic process 10 83 3.50 12
coenzyme metabolic process 12 100 3.82 12
alcohol metabolic process 27 228 5.69 12
cellular lipid metabolic process 52 472 7.39 11
glycoprotein biosynthetic process 12 110 3.45 11
glycoprotein metabolic process 14 131 3.64 11
protein amino acid glycosylation 11 103 3.22 11
biopolymer glycosylation 11 105 3.15 10
fatty acid metabolic process 14 141 3.33 10
isoprenoid biosynthetic process 5 15 5.56 33
Signal transduction
activation of phospholipase C activity 2 12 2.12 17
peptidyl-tyrosine modiﬁcation 5 36 2.85 14
positive regulation of I-kappaB kinase/NF-kappaB cascade 9 78 3.17 12
az-score  3.0, as determined by GeneSifter& Software Analysis and  5 transcripts per ontology, with signiﬁcant transcripts representing at least 10% of ontology on array.
b% determined by number of transcripts in ontology list divided by total number of transcripts in ontology on array.
LH/steroid ablation/replacement in primate CL 187PGR (Table IV and Fig. 4A), the AR and estrogen receptor b (AR and
ESR2, respectively; Table IV). The only putative steroid hormone
receptor whose transcript levels differed signiﬁcantly with treatment,
based on microarray and real-time PCR analyses, was the non-classical
progestin receptor: progesterone receptor membrane component 1
(PGRMC1; Fig. 4B). This transcript was highly expressed, but the
pattern of mRNA expression differed between real-time PCR data
and the microarray for both A þ LH and A þ LH þ TRL treatment
groups (Fig. 4B).
Two gene products, StAR protein and SFRP4, were chosen to
determine whether there was any correlation between their mRNA
and protein levels. One gene displayed high levels of mRNA
expression (StAR; Fig. 5A), whereas expression of mRNA for the
other gene was moderate (SFRP4; Fig. 6A). Again, the patterns of
expression for mRNA data from real-time PCR matched microarray
analysis for both genes. The mRNA levels for StAR were markedly
decreased by Antide treatment, but maintained near-control levels
by LH replacement, and comparable results were obtained by TRL
treatment and R5020 replacement (Fig. 5A). Notably, the pattern of
StAR protein levels between treatment groups was similar to that of
mRNA levels (Fig. 5B). In contrast, SFRP4 mRNA levels increased
6-fold with Antide treatment, and replacement of LH reduced, but
did not completely restore mRNA to control levels; TRL treatment
with or without R5020 replacement had a minimal effect when
measured by real-time PCR (Fig. 6A). Although the levels of protein
for SFRP4 changed signiﬁcantly across treatment groups (Fig. 6B;
P , 0.001), the expression pattern of the protein did not match
that of the mRNA. Protein levels were unchanged between LH abla-
tion and replacement groups, whereas steroid ablation by TRL treat-
ment lowered the expression levels, and R5020 replacement had no
further effect. The western blots for pooled samples for StAR and
SFRP4 are shown in Fig. 7.
Discussion
This study provides a genome-wide analysis of macaque luteal tran-
scripts that are either directly or indirectly regulated by LH. All nor-
malized data ﬁles have been uploaded to the National Center for
Biotechnology Information’s Gene Expression Omnibus gene
expression repository (http://www.ncbi.nlm.nih.gov/geo/; series
GSE12281), which allows for further analyses to be performed by
independent investigators. The current microarray analysis conﬁrmed
earlier reports of LH-regulated transcripts in macaque luteal tissue.
For example, our preliminary analysis of LH-regulated genes in the
macaque CL from Antide-treated monkeys identiﬁed CRHBP
mRNA as markedly up-regulated by LH withdrawal (Xu et al.,
2005). This evidence led to the detailed characterization of a novel
local system in the macaque CL—the CRH/UCN receptor-binding
protein system—that may modulate LH action and hence regulate
primate luteal structure–function (Xu et al., 2007). The current
............................................................................................................. ........................................
.............................................................................................................................................................................................















AR 65+5 ;C ;C ;C ;C >0.9 Yes
CASP2 16+1 ;C ;C ;C ;C >0.2 Yes
ESR2 23+2 ;C ;C ;C ;C >0.6 Yes
PGR 11+1 ;C ;C ;C ;C >0.6 Yes
LH
Regulated
AHRIP 124+12 #" ;LH ;LH ,0.01 No




ARNT2 39+5 "# " # ,0.01 Yes
CRHBP 75+30 "# " trend # ,0.001 Yes
LOC693394 26+9 trend "# " # ,0.03 Yes
SFRP4 30+5 "# " # ,0.02 Yes
SC4MOL 2774+369 #" # " ,0.02 Yes





ADAMTS5 24+5 #" # ;TRL ,0.01 Yes
CAT 2803+445 #" # ;TRL ,0.05 Yes
Inhibin BA 679+138 #" # ;TRL >0.3 Yes
PRLR 87+18 #" # ;TRL ,0.01 Yes
VEGF 282+26 #" # ;TRL ,0.05 Yes
CCL3 133+64 "# " ;TRL >0.06 Yes
MHC1 383+232 " trend #" ;TRL ,0.01 No
MMP19 132+18 "# " ;TRL ,0.05 Yes
MMP9 116+35 "# trend " ;TRL ,0.05 No
PGRMC1 2109+82 "# " ;TRL ,0.01 No
Control values (+SEM) are presented as a reference. Direction of expression of validated genes by microarrayanalysis is compared with previous group (e.g. A compared with C), except
for genes whose expression did not differ from control. One-way ANOVA values of signiﬁcance are presented for real-time PCR validation.
188 Bishop et al.Figure 3 A list of transcripts identiﬁed by GeneSifter& from the KEGG ontology ‘Steroid Biosynthetic Process’ (similar to Table III) as signiﬁcantly
(one-way ANOVA, P , 0.05) affected by treatments is shown in Panel A (blue indicates minimum expression, whereas red indicates maximum
expression). The red stars indicate the relative expression of transcripts for the PRLR and SC4MOL. Real-time PCR results for PRLR (Panel B;
one-way ANOVA, P , 0.01) and SC4MOL (Panel C; one-way ANOVA, P ¼ 0.01) are compared with microarray results (P , 0.05). See the
legend of Fig. 2 for more details.
Figure 2 A list of regulated transcripts identiﬁed by GeneSifter& from the KEGG ontology ‘Negative Regulation of Immune System Process’ (as in
Table III) as signiﬁcantly (one-way ANOVA, P , 0.05) affected by treatments is shown in Panel A (blue indicates minimum expression, whereas red
indicates maximum). A comparison of interleukin 1 receptor antagonist (IL1RN; mean+SEM) results is depicted in Panel B, with white bars repre-
senting microarray values (GeneSifter& one-way ANOVA, P , 0.05), and black bars representing real-time PCR data (one-way ANOVA, P , 0.001;
different letters signify treatment groups with signiﬁcantly different values, P , 0.05).
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and, possibly, action, with the ﬁnding that steroid withdrawal and
R5020 replacement mimicked the effects of Antide treatment and
LH replacement. Thus, CRHBP appears indirectly regulated by LH
via steroid hormone production, particularly the local actions of
P. Also, the current results conﬁrm and extend the evidence from
differential gene display in the bonnet monkey CL that LH withdrawal
markedly suppressed the expression of LDL receptor mRNA, a key
membrane component for cholesterol uptake into primate luteal
cells (Yadav et al., 2004).
However, the current analysis also identiﬁed many novel transcripts
whose expression is LH-regulated in the macaque CL. For example,
mRNA for the IL1RN, a suppressor of the immune system, that
was ﬁrst detected in the ovaries of rats (Kol et al., 1999) and later
reported to increase interleukin-1b-stimulated prostaglandin (E, F2a)
release from human luteal cells (Miceli et al., 2003), was up-regulated
by LH withdrawal. This LH action appears independent of local steroid
action, since LH treatment restored IL1RN mRNA to control levels
and steroid withdrawal did not mimic the effect of Antide treatment.
Unexpectedly, PRLR mRNA expression in the macaque CL was
down-regulated by LH withdrawal. Unlike in some non-primate
species [e.g. rodents (Herz et al., 1986)], PRL and PRL-like hormones
are not considered major luteotropic hormones for the primate CL
(Stouffer, 2006). However, a recent microarray analysis (Bogan
et al., 2008b) of gene expression in the macaque CL throughout the
menstrual cycle discovered appreciable PRLR expression that declined
at luteolysis; moreover, the expression pattern for PRLR mRNA and
protein were comparable. There are high levels of prolactin (-like) pro-
teins circulating during pregnancy and lactation (Bachelot and Binart,
2007). The possibility proposed by Knobil and colleagues (Richardson
et al., 1985) that PRLR ligands could contribute to the maintenance of
luteal function in primates, perhaps during pregnancy and lactation,
warrants re-evaluation.
Notably, a small but signiﬁcant number (n ¼ 36, Fig. 1B and Table II)
of Antide-sensitive transcripts in the macaque CL were not affected by
LH replacement. Of particular interest is the expression of LDL recep-
tor (discussed earlier), a key component in cholesterol entrance into
the cell, and prostaglandin F receptor (PTGFR), a potent, local and
perhaps physiologic luteolytic factor in primates (Yadav et al., 2004;
Bogan et al., 2008a). Expression of both LDL receptor mRNA and
PTGFR declined markedly with Antide treatment, and this effect
was not signiﬁcantly altered by LH replacement. Although the
LH-replacement regimen restored the expression of many Antide-
sensitive gene products, and this regimen prevents the functional–
structural regression of the CL in Antide-treated monkeys (Duffy
et al., 1999b), it is possible that our LH protocol was sub-optimal
for a cohort of LH-regulated genes. Alternatively, there is evidence
of GnRH receptor expression (Chakrabarti et al., 2008) and GnRH
effects (Siler-Khodr et al., 2004) in primate ovaries and CL. Though
it is currently controversial whether GnRH serves as an important
Figure 4 Microarray and real-time PCR expression patterns for the
genomic PGR (Panel A; GeneSifter& and real-time PCR one-way
ANOVA, P . 0.6) and P receptor membrane component 1
(PGRMC1; Panel B; GeneSifter& one-way ANOVA, P , 0.05; real-
time PCR one-way ANOVA, P , 0.01). Statistics for PGR and
PGRMC1 are depicted for real-time PCR results (mean+SEM),
with white bars representing microarray values, and black bars repre-
senting real-time data. Different letters signify treatment groups with
signiﬁcantly different values (P , 0.05).
Figure 5 StAR mRNA expression (Panel A; white bars indicate
microarray data, black bars indicate real-time data: see the legend
of Fig. 2 for more details on microarray and real-time data;
one-way ANOVA, P , 0.001) and protein levels (Panel B; one-way
ANOVA, P , 0.001; means+SEM) in individual CL normalized to
b-actin as compared between treatment groups.
190 Bishop et al.local factor in primates, as it does in rodents (Gupta and Flaws, 2005),
we cannot rule out that Antide affects luteal GnRH signaling and
action. Indeed, the Antide-sensitive, LH-insensitive gene products
could be markers of local GnRH action in the primate CL.
Of the approaching 1500 LH-sensitive transcripts in the macaque
CL, less than one-third of this cohort was affected similarly by
steroid ablation, and even fewer by progestin replacement (Fig. 1B).
This evidence implies that many LH-regulated genes are independent
of steroid action; their expression may be regulated directly by LH sig-
naling pathways, or indirectly by other LH-regulated local factors (e.g.
CRH/UCN, VEGF, PGs) or LH-regulated receptors/binding proteins
for other hormones or local factors (PRLR, CRHBP) in the CL. That
progestin replacement only restored transcript levels for some genes
may again (as for LH replacement) be a limitation of our R5020
regimen. Nevertheless, this regimen prevents endocrine and histologi-
cal indices of functional and structural luteolysis (Young and Stouffer,
2004), in the macaque CL, and unequivocally restored mRNA levels
of select steroid-sensitive genes (see what follows). It is possible
that the numbers or types of cells expressing some of these steroid-
sensitive transcripts changed after 3 days of treatment. Previous histo-
logical analyses of Antide- and A þ LH þ TRL-treated CL revealed
that steroidogenic cells were smaller in volume, and the numbers of
immune cells were greater, compared with control, AþLH and A þ
LH þ TRL þ R5020 treatments (Young and Stouffer, 2004); but
these observations were qualitative. Alternatively, it is possible that
by mid-late luteal phase (Day 9–12), the CL is not as responsive to
progestin as luteal tissue from the early-to-mid-luteal phase. We
reported previously that the percent of PR-positive cells and PR
mRNA levels in the macaque CL decline after mid-luteal phase (Hild-
Petito et al., 1988; Duffy et al., 1999b). Moreover, there is evidence
that gene expression in the CL in response to steroid withdrawal
and progestin replacement differs between the early and mid-late
luteal phase [e.g. ADAMTS-1, a disintegrin and metalloproteinase
with thrombospondin repeats-1 (Young et al., 2004)]. This differential
response could also be related to changes in the ratio of PR A:B iso-
forms as the luteal lifespan progresses (Duffy et al., 1997). The current
analysis also detected appreciable mRNA levels for the novel mem-
brane progestin receptor PGRMC1 in macaque luteal tissue. A physio-
logic role for PGRMC1 in the CL has yet to be deﬁned, but it could
play a role in mediating the LH-like, luteotropic effects of P by prevent-
ing apoptosis of luteinized cells (Engmann et al., 2006). Finally, since
the 3b-HSD inhibitor, TRL, markedly suppresses production of
other steroids relying on P as a precursor, those steroid-sensitive tran-
scripts that were not restored by R5020 replacement could be altered
by androgen or estrogen withdrawal. The macaque CL expresses AR
and ER (particularly ERb) during its lifespan (Duffy et al., 1999a, 2000).
Moreover, Duffy et al. (2000) reported that ERb mRNA levels
decreased around luteolysis and that steroid withdrawal at mid-luteal
phase (Day 6) increased ERb expression, whereas R5020 replacement
returned expression to control levels. Further studies are needed at
earlier stages of luteal development and function, and while replacing
estrogen or androgen, as well as progestin, to clarify the LH- and
steroid-regulated gene processes in the primate CL.
Nevertheless, the changes in mRNA levels of several genes in
response to LH withdrawal and replacement were mimicked by
steroid withdrawal and progestin replacement. For example, StAR
expression exhibited a similar pattern following either withdrawal/
replacement regimen (Fig. 5), strongly suggesting that the changes
evoked by LH were indirect and are due to LH-stimulated P pro-
duction by the tissue. Abundant levels of StAR protein are expressed
Figure 6 SFRP4 expression in ablation/replacement CL. See the
legend of Fig. 5 for details. The pattern of SFRP4 protein expression,
although signiﬁcant (one-way ANOVA, P , 0.001), does not match
the expression of SFRP4 mRNA (real-time PCR one-way ANOVA,
P , 0.02).
Figure 7 Representative immunoblots for StAR, SFRP4 and b-actin
loading control for pooled samples of different treatment groups.
Note that as presented in Fig. 5A and B, StAR protein expression
matches mRNA expression patterns, whereas SFRP4 protein
expression does not match mRNA expression. b-Actin was used
for loading control.
LH/steroid ablation/replacement in primate CL 191in the developing and developed human CL, and these levels decline
between the mid- and late-luteal phase (Devoto et al., 2001). Like-
wise, expression of other enzymes in the ontology ‘steroid biosyn-
thetic processes’ (Fig. 3), SC4MOL and CYP19A1, exhibited a
similar pattern following either LH or steroid withdrawal/replacement
regimen. Thus, P may regulate a select number of key genes that are
critical for luteal structure–function around the onset of luteolysis at
mid-late luteal phase. As noted from our initial analyses of mRNA
and protein levels, it will be important to follow genomic analyses
with evaluations of the translation and activity of gene products. The
patterns of mRNA and protein expression were similar for StAR,
suggesting that transcriptional regulation is a key part of progestin
regulation of StAR production. However, the patterns of mRNA
and protein levels for secreted frizzled related protein 4 (SFRP4)
were not comparable, suggesting that regulation of SFRP4 can occur
at the translational level. This concept is consistent with previous evi-
dence (Young and Stouffer 2004; Peluffo et al., 2005) that LH/proges-
tin regulation of proteases (caspases, MMPs) can occur at either/both
the mRNA, protein or enzyme activity level. Further analysis of the
actions of LH and steroids at the transcriptional, translational and
post-translational levels is needed to understand the regulation of
luteal structure–function in primates.
In summary, this microarray experiment broadly deﬁnes the
changes in gene expression in the primate CL that are regulated by
LH around the onset of luteolysis in the menstrual cycle. The data
suggest that LH regulates the expression of many genes involved in
the maintenance of CL structure–function independently of steroid
action. However, steroid withdrawal and R5020 replacement indicate
that progestin is involved in the regulation of key pathways that regu-
late the CL lifespan (Stouffer, 2003), and this may involve actions via a
non-classical PR. Also, steroid-sensitive genes whose activity was not
restored by R5020 replacement could be regulated by androgens or
estrogens. Further studies on LH/steroid withdrawal and replacement
during CL development in the early-luteal phase and analysis of the
patterns of both mRNA and protein expression in macaque CL are
needed. During revision of this manuscript, a microarray analysis of
a limited sample of primate CL after short-term LH ablation was pub-
lished online (Priyanka et al., 2008). Comparisons of similar studies will
help to elucidate the relative roles of LH and steroids on gene
expression in the primate CL during the menstrual cycle.
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